Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Vanita R. Aroda,1 Julio Rosenstock,2 Carol Wysham,3 Jeffrey Unger,4 Diego Bellido,5 Guillermo Gonzalez-G ́ alvez, ́ 6 Akane Takami,7 Hailing Guo,8 Elisabeth Niemoeller,9 Elisabeth Souhami,10 and Richard M. Bergenstal,11 on behalf of the LixiLan-L Trial Investigators *** Diabetes Care 2016;39:1972–1980 | DOI: 10.2337/dc16-1495